Siegfried and Keryx Biopharmaceuticals Inc have entered into a master manufacturing services and supply agreement. Under the agreement, Siegfried will perform certain manufacturing activities at its manufacturing facilities in Saint Vulbas, France and Pennsville, New Jersey as well as to manufacture and supply GMP-grade quantities of the proprietary active pharmaceutical ingredient for Keryx’s drug product, Auryxia.
The agreement has an initial term ending on 31 December 2021 and will automatically renew after that for successive terms of one year each.
No comments:
Post a Comment